EUCTR2007-007633-39-ES进行中（未招募）1 期
Estudio fase 2 aleatorizado, controlado con placebo, de doble ciego sobre la eficacia de MORAb-009 en combinación con gemcitabina en pacientes con cáncer de páncreas avanzado
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female or male subjects, = 18 years of age, with cytologically or histologically confirmed diagnosis of pancreatic adenocarcinoma.
- •2.Must have measurable disease, as defined by RECIST (see Appendix B) or evaluable by clinical signs/symptoms (e.g. ascites, pleural effusion, or lesions of less than 2 cm) supported by biomarker, radiologic, or pathologic studies conducted within 4 weeks prior to study entry.
- •3.Must have unresectable disease and have received no prior chemotherapy or radiation therapy for their pancreatic cancer.
- •4.Karnofsky performance status of greater than or equal to 70 % (see Appendix D).
- •5.Female subjects of childbearing potential and all male subjects must be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period.
- •6.Other significant medical conditions must be well-controlled and stable in the opinion of the investigator for at least 30 days prior to Study Day 1.
- •7.Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:
- •Absolute neutrophil count (ANC)= 1.5 x 109/L
- •Platelet count= 100 x 109/L
- •Hemoglobin= 9 g/dL
- •Serum bilirubin= 2.0 mg/dL
- •Aspartate transaminase (AST)*= 5 x upper limit of normal (ULN)
- •Alanine transaminase (ALT)*= 5 x ULN
- •Alkaline phosphatase*= 5 x ULN
- •Serum creatinine= 2.0 mg/dL
- •Stenting to reduce liver functions to qualifying levels is permitted.
- •* Subjects with liver function abnormalities greater than the ULN are eligible only if in the opinion of the investigator they are due to disease obstruction of the bile ducts or metastatic disease.
- •8.Must be willing and able to provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known central nervous system (CNS) tumor involvement.
- •2.Evidence of other active malignancy requiring treatment.
- •3.Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months).
- •4.Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note: Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia [SVT], are eligible).
- •5.Active serious systemic disease, including active bacterial or fungal infection.
- •6.Active viral hepatitis or symptomatic human immunodeficiency virus (HIV) infection.
- •7.Prior chemotherapy or radiation therapy for their pancreatic cancer.
- •8.Breast-feeding, pregnant, or likely to become pregnant during the study.
- •9.No other concurrent immunotherapy (e.g., immunosuppressants or chronic use of systemic corticosteroids with the exception that low-dose corticosteroids are allowed)
- •10.Known hypersensitivity to a monoclonal antibody or biologic therapy.
研究者
相似试验
进行中（未招募）
2 期
Effect of Baricitinib on Insulin Production in Type 1 DiabetesMetabolic and Endocrine - DiabetesType 1 Diabetes MellitusACTRN12620000239965St Vincent’s Institute of Medical Research91
进行中（未招募）
不适用
A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancer - metformin and pancreatic cancerlocally advanced and metastatic pancreatic cancerMedDRA version: lltLevel: LLTClassification code 10033604Term: <Manually entered code. Term in E.1.1>EUCTR2009-017716-32-NLAcademic Medical Center
已完成
2 期
A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancermetastatic pancreatic cancer10017991NL-OMON34831Academisch Medisch Centrum120
招募中
1 期
A study to investigate EDP2939 in healthy volunteers and participants with moderate psoriasis.EUCTR2022-001631-82-PLEvelo Biosciences, Inc.146
进行中（未招募）
1 期
A study to investigate EDP2939 in healthy volunteers and participants with moderate psoriasis.EUCTR2022-001631-82-BGEvelo Biosciences, Inc.146